Normal ambulatory blood pressure in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy
- PMID: 35929901
- PMCID: PMC9983799
- DOI: 10.20945/2359-3997000000504
Normal ambulatory blood pressure in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy
Abstract
Objective: Herein, we compared ambulatory blood pressure (ABP) between young adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase enzyme (21OHase) deficiency and a control group. Additionally, we analyzed correlations between the glucocorticoid dose and androgen levels and ABP parameters.
Subjects and methods: This case-control study included 18 patients (6 males and 12 females) and 19 controls (8 males and 11 females) matched by age (18-31 years). ABP monitoring was used to estimate blood pressure (BP) over a 24-h period.
Results: No difference was noted between patients and controls in terms of systolic BP (males, 115.5 ± 5.6 vs. 117.0 ± 9.3, P = 0.733; and females, 106.4 ± 7.9 vs. 108.4 ± 7.6, P = 0.556, respectively) and diastolic BP during 24 h (males, 62.8 ± 7.5 vs. 66.2 ± 5.6, P = 0.349; and females, 62.7 ± 4.9 vs. 62.3 ± 4.9, P = 0.818, respectively). Systolic and diastolic BP and pulse pressure during daytime and nocturnal periods were similar between patients and controls. Furthermore, no differences were detected in the percentage of load and impaired nocturnal dipping of systolic and diastolic BP between patients and controls during the 24-h period. Additionally, the glucocorticoid dose (varying between r = -0.24 to 0.13, P > 0.05) and androgens levels (varying between r = 0.01 to 0.14, P > 0.05) were not associated with ABP parameters.
Conclusion: No signs of an elevated risk for hypertension were observed based on ABP monitoring in young adults with CAH attributed to 21OHase deficiency undergoing glucocorticoid replacement therapy.
Keywords: Cardiovascular risk; congenital adrenal hyperplasia; hydrocortisone; hypertension.
Conflict of interest statement
Disclosure: no potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia--a preliminary report.J Pediatr Endocrinol Metab. 2004 Aug;17(8):1089-95. doi: 10.1515/jpem.2004.17.8.1089. J Pediatr Endocrinol Metab. 2004. PMID: 15379420 Clinical Trial.
-
Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.Clin Endocrinol (Oxf). 2003 May;58(5):589-96. doi: 10.1046/j.1365-2265.2003.01757.x. Clin Endocrinol (Oxf). 2003. PMID: 12699440
-
Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.Osteoporos Int. 2022 Jan;33(1):283-291. doi: 10.1007/s00198-021-06097-w. Epub 2021 Aug 18. Osteoporos Int. 2022. PMID: 34406442
-
Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.Cochrane Database Syst Rev. 2020 Mar 19;3(3):CD012517. doi: 10.1002/14651858.CD012517.pub2. Cochrane Database Syst Rev. 2020. PMID: 32190901 Free PMC article.
-
Blood Pressure in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.Horm Res Paediatr. 2024;97(4):315-325. doi: 10.1159/000533465. Epub 2023 Aug 23. Horm Res Paediatr. 2024. PMID: 37611560 Review.
Cited by
-
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.Endocr Rev. 2025 Jan 10;46(1):80-148. doi: 10.1210/endrev/bnae026. Endocr Rev. 2025. PMID: 39240753 Free PMC article. Review.
References
-
- Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409–413. - PubMed
-
- Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, Prokop LJ, Bancos I, Speiser PW, et al. Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(11):4097–4103. - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical